首页
>
期刊首页
>
基因与疾病(英文)
>
2026年1期
>
Targeting Wnt/β-catenin activation in combination with temozolomide leads to glioblastoma inhibition and long-term survival in mice
Targeting Wnt/β-catenin activation in combination with temozolomide leads to glioblastoma inhibition and long-term survival in mice
摘要
Glioblastoma(GBM)is one of the most treatment-resistant brain malignancies.Dys-regulation of Wnt/β-catenin signaling might be implicated in tumorigenesis of GBM.In this study,spatial transcriptomic analysis revealed elevated expression of Wnt target genes within tumor regions compared with peritumoral tissues.Overexpression of porcupine(PORCN),an O-acyltransferase for Wnt secretion,correlated with poor prognosis of GBM patients.Treatment with Wnt-C59,a PORCN inhibitor,inhibited Wnt signaling,hindered GBM cell proliferation and invasion,and inhibited GBM stem cells' self-renewal properties in a dose-dependent manner.Moreover,using β-catenin knockout and knockdown cells,FOXM1 was identified as a down-stream transcription target of Wnt/β-catenin signaling.Wnt-C59 inhibited the expression of FOXM1 in GBM cells.Furthermore,Wnt-C59 demonstrated the ability to impede tumor forma-tion and enhance the overall survival of mice bearing GBM in a preclinical model.Notably,the combined treatment of Wnt-C59 with temozolomide further enhanced therapeutic outcomes,leading to a significant extension of overall survival in GBM-bearing mice.Mechanistically,Wnt-C59 significantly down-regulated the expression of oncogenic targets associated with Wnt/β-catenin signaling(FOXM1,cyclin D,and C-Myc)both in vitro and in orthotopic GBM models.Our findings reveal that targeting Wnt/β-catenin signaling via PORCN inhibition,especially in combination with temozolomide,offers a promising therapeutic strategy for treating GBM.
年,卷(期):
2026, 13(1)
机标分类号:
R722.6
R285.5
R978.16
在线出版日期:
2026年4月21日